Crisugabalin
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Crisugabalin
- Molecular weight
- 209.29
- Structure (SMILES)
- NC[C@@]1(CC(=O)O)[C@@H]2CC[C@H]3C[C@@H]2[C@@H]1C3
- crisugabalin
- Crisugabalin
- crisugabalin [INN]
- Crisugabalin [WHO-DD]
- Crisugabalin 20mg bid
- crisugabalin inn
- crisugabalin who dd
- Crisugabalin(HSK16149) 20mg qd
- Crisugabalin(HSK16149)20mg BID
- crisugabalina
- Crisugabalina
- crisugabaline
- Crisugabaline
- hsk 16149
- HSK-16149
- hsk16149
- Hsk16149
- HSK16149
- HSK16149 20mg BID
- HSK16149 20mg-40mg BID
- HSK16149 40mg BID
- HSK16149 60mg BID
- HSK16149 80mg BID
- HSK16149 capsule
- CAS registry numbers
- 2209104-84-5
- ChEMBL ID
- CHEMBL5314958
- InChIKey
- WCEFMBSFXJUREW-LIJGXYGRSA-N
- PubChem compound IDs
- 139300919
- FDA ingredient codes (UNII)
- Q3MK7E8686
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- crisugabalin
- Type
- Synthetic organic
- Drug name stem
- -gab-
- Approval recorded by Guide to Pharmacology
- Yes
- Condition
- Kidney Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003086
- Subject identifier
- D007674
- Condition
- Pain
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003843
- Subject identifier
- D010146
- Condition
- Neuralgia
- Highest recorded phase
- 3
- Condition identifier
- EFO:0005762
- Subject identifier
- D009437
- Condition
- Herpes Zoster
- Highest recorded phase
- 2
- Condition identifier
- EFO:0006510
- Subject identifier
- D006562
- Condition
- Diabetic Neuropathies
- Highest recorded phase
- 1
- Condition identifier
- EFO:1000783
- Subject identifier
- D003929
- Condition
- Neuralgia, Postherpetic
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0041052
- Subject identifier
- D051474
- Condition identifier
- EFO_0003086
- Highest recorded phase
- 1
- Condition identifier
- EFO_0005762
- Highest recorded phase
- 3
- Condition identifier
- EFO_1000783
- Highest recorded phase
- 1
- Condition identifier
- HP_0012531
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0001942
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005391
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005546
- Condition identifier
- MONDO_0005609
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005627
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0041052
- Highest recorded phase
- 3
- NCT04647773
- NCT05890053
- NCT04841720
- NCT05140863
- NCT05763550
- NCT05916573
- NCT06007066
- Hydrogen bond acceptors
- 2
- Hydrogen bond donors
- 2
- Polar surface area
- 63.32
- Calculated partition coefficient (ALogP)
- 1.47
- Calculated partition coefficient (XLogP)
- -0.9
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 3
- Heavy atoms
- 15
- Molecular formula
- C12H19NO2
- Monoisotopic mass
- 209.141578849
- Natural product
- No
Related records
Trials (19)
- A Study Evaluating Drug-Drug Interaction (DDI) Between HSK16149 Capsules and Metformin Hydrochloride Tablets
- A Study to Evaluate the Pharmacokinetics of HSK16149 in Subjects With Renal Impairment
- Crisugabalin for Radiotherapy-Related Neuropathic Pain
- Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial
- Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Diabetic Peripheral Neuropathic Pain Who Had an Inadequate Response to Pregabalin
- Efficacy and Safety of HSK16149 Capsule in the Treatment of Moderate and Severe Central Neuropathic Pain in China
- HSK16149 for Perioperative Analgesia in Orthopedic Surgery
- Novel Calcium Channel Modulators in RLS and Variants: Efficacy & Safety
- Prospective Clinical Trial of Crisugabalin Capsules in the Treatment of Generalized Anxiety Disorder
- Real-World Study of Crisugabalin(HSK16149) for the Treatment of Rosacea
- RELIEF-PD: Crisugabalin for Nociplastic Pain in Parkinson's Disease
- The Analgesic Efficacy and Safety of Crisugabalin in Patients With Herpes Zoster
- The Drug-drug Interaction of HSK16149 Capsule With Probenecid Tablets or Cimetidine Tablets in Healthy Subjects
- The Efficacy and Safety of Pregabalin and Crisugabalin in Patients With Fibromyalgia
- To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Diabetic Peripheral Neuropathic Pain
- To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Herpetic Neuralgia
- To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Postherpetic Neuralgia
- To Evaluate the Efficacy and Safety of HSK16149 With L-carnitine in Diabetic Peripheral Neuralgia Patients in China
- To Evaluate the Long-term Safety and Efficacy of HSK16149 in Chinese Patients With Peripheral Neuralgia
In development for (5)
- Diabetic neuropathy Phase 1
- Herpes zoster Phase 2
- Kidney disorder Phase 1
- Neuralgia Phase 3
- Postherpetic neuralgia Phase 3